A5022243742- RNA and protein synthesis mechanisms
- Genomics and Chromatin Dynamics
- Protein Degradation and Inhibitors
- Biotin and Related Studies
- Advanced biosensing and bioanalysis techniques
- CRISPR and Genetic Engineering
- Immunotherapy and Immune Responses
- RNA modifications and cancer
- Infectious Diseases and Mycology
- vaccines and immunoinformatics approaches
- RNA Research and Splicing
- Virus-based gene therapy research
- BRCA gene mutations in cancer
- CAR-T cell therapy research
- Animal Genetics and Reproduction
- Chronic Myeloid Leukemia Treatments
- Melanoma and MAPK Pathways
- Epigenetics and DNA Methylation
- Veterinary Oncology Research
- PI3K/AKT/mTOR signaling in cancer
Stanford University
2014-2025
VA Palo Alto Health Care System
2014
Sidney Kimmel Comprehensive Cancer Center
2013
Thousands of putative enhancers are characterized in the human genome, yet few have been shown to a functional role cancer progression. Inhibiting oncokinases, such as EGFR, ALK, ERBB2, and BRAF, is mainstay current therapy but hindered by innate drug resistance mediated up-regulation HGF receptor, MET. The mechanisms mediating genomic responses targeted unknown. Here, we identify lineage-specific at MET locus for multiple common tumor types, including melanoma enhancer 63 kb downstream from...
Gene expression is controlled by transcription factors (TFs) that bind cognate DNA motif sequences in cis-regulatory elements (CREs). The combinations of motifs acting within homeostasis and disease, however, are unclear. expression, chromatin accessibility, TF footprinting, H3K27ac-dependent looping data were generated a random-forest-based model was applied to identify 7,531 cell-type-specific modules (CRMs) across 15 diploid human cell types. A co-enrichment framework CRMs nominated 838...
The ability to target myeloid leukemia with immunotherapy would represent a significant therapeutic advance. We report here immunological analysis of clinical trials primary and secondary vaccination K562/GM-CSF in adult chronic phase patients (CML-CP) suboptimal responses imatinib mesylate. Using serological recombinant cDNA expression libraries K562 autologous vaccinated patient serum, we have identified 12 novel leukemia-associated antigens (LAAs). show that following are associated...
Canine oral mucosal melanoma is an aggressive malignant neoplasm and characterized by local infiltration a high metastatic potential. The disease progression similar to that of human melanomas. Whereas cutaneous primarily driven activating mutations in Braf (60%) or Nras (20%), harbors these much less frequently. This makes therapeutic targeting research modeling the form potentially different from humans. Similarly, has found only rare no canine melanomas, but they are still reliant on MAPK...
Abstract BACKGROUND: Human cutaneous melanoma is primarily driven by activating mutations in Braf (60%) or Nras (20%). However, human oral harbors these much less frequently. Similarly, canine mucosal melanomas have not been found to mutations. This makes them an ideal model study alternative means of ERK1/2 MAPK pathway activation as tumors are still reliant on signaling. We previously studied IQGAP1 a tumor specific scaffold and shown that it required for cancer progression. METHODS: In...